Coherus BioSciences

#5334

Rank

$503.28M

MarketCap US

US United States

Country

Summary
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

History

Coherus BioSciences was founded in 2010 by former Amgen and Biogen Idec colleagues to pursue opportunities in the global biosimilars market. From the beginning, Coherus combined a deep understanding of biologics development and a global mindset to build a leading company in the biosimilars space.


Mission
Coherus is committed to providing world-class biopharmaceuticals to improve the lives of patients worldwide.

Vision
Our vision is to become a worldwide leader in the development, manufacturing and commercialization of innovative, affordable biopharmaceuticals.

Key Team

Mr. Bryan J. Mcmichael (Sr. VP of Accounting, Principal Accounting Officer & Corp. Controller)

Mr. Richard L. Hameister (Chief Technical Officer)

Mr. Christopher W. Slavinsky (Chief Bus. & Legal Officer)

Cheston Turbyfill (VP of Communications)

Ms. Karen Kotz (Exec. VP of Sales & Strategic Accounts)

Ms. Rebecca Sunshine (Chief HR Officer)

Mr. Michael Chen (Sr. VP of Commercial Analytics & Trade)


Recognition and Awards
Coherus has been the recipient of numerous awards, including The San Francisco Business Times’ Fast 100 Award in 2014, The SVBJ’s Top 10 Finalist in 2015 and The Business Journal’s 40 Under 40 in 2015.

References
Coherus BioSciences
Leadership team

Mr. Dennis M. Lanfear (Chairman, Pres & CEO)

Mr. McDavid Stilwell (Chief Financial Officer)

Mr. Vladimir Vexler Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology, Health Care, Manufacturing, Medical, Therapeutics
Number of Employees
100 - 500
Headquarters
Redwood City, California, United States
Established
2007
Company Registration
SEC CIK number: 0001512762
Revenue
100M - 500M
Traded as
CHRS
Social Media
Sun Mar 03 2024
About

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with
Logo

Copyright 2023 © businessabc powered by ztudium